BioNTech’s Pumitamig Delivers 100% Response Rate as German Reform Clouds the Home Front

BioNTech's bispecific antibody Pumitamig achieves up to 100% response rates in NSCLC, but German healthcare reforms and factory closures threaten its oncology pivot.

BioNTech is riding a wave of stunning clinical data for its bispecific antibody Pumitamig, but the company’s home market is creating a fresh headwind that could complicate its transition to an oncology powerhouse. Interim results from the global Phase 2/3 ROSETTA Lung-02 study, presented at the ASCO congress, showed confirmed objective response rates climbing as high as 72.7% in previously untreated advanced non-small cell lung cancer (NSCLC), depending on subtype. Among patients with high PD-L1 expression, that figure hit 100%, while the disease control rate across all subgroups also reached 100%, all with a manageable safety profile for both squamous and non-squamous tumors.

The data have thrust Pumitamig — also known as BNT327 or BMS-986545 — into the center of BioNTech’s oncology strategy. The drug is now being evaluated in three global Phase 3 NSCLC trials, and its reach extends well beyond lung cancer. Studies are underway in hepatocellular carcinoma, glioblastoma, pancreatic cancer, and renal cell carcinoma, either as a monotherapy or in combination with established treatments. BioNTech aims to have 15 ongoing Phase 3 oncology studies by the end of 2026, with multiple late-stage data readouts expected in the same year. The pipeline currently includes more than 25 Phase 2 and Phase 3 trials, 13 of which are registration studies.

Yet even as the science advances, Berlin is moving in the opposite direction. The federal government’s proposed GKV-Beitragssatzstabilisierungsgesetz (GKV-BStabG) would introduce sweeping cost-containment measures designed to shave nearly €20 billion off healthcare spending by 2027 and more than €42 billion by 2030. New pricing rules and mandatory rebates could severely constrain the reimbursement environment for innovative therapies. BioNTech has joined a growing industry coalition opposing the plans, and the stakes are high: the law is expected to pass before the summer recess and take effect in January 2027, exactly when the company’s first cancer products could be reaching the German market.

The domestic headwinds are compounded by a deep restructuring of BioNTech’s manufacturing footprint. By the end of 2027, the company will close three German sites — Idar-Oberstein, Marburg, and Tübingen — along with a factory in Singapore. Up to 1,860 jobs are affected, though annual savings of roughly €500 million are targeted from 2029 onward to fund oncology development. Critics argue the timing is poor, with Germany dismantling its biotech infrastructure just as the government tightens investment conditions.

Wall Street analysts remain split on the stock’s prospects. UBS upgraded the shares from Neutral to Buy after the ASCO data, lifting its price target from $117 to $135, citing greater confidence in the late-stage pipeline, particularly around Pumitamig and the immuno-oncology candidate Gotistobart. Bernstein’s Jeffrey Walch took a more cautious stance, initiating coverage with a Hold rating and a $96 target, offering little upside from current levels. The share price reflects the uncertainty: BioNTech trades at €76.30, down roughly 22% over the past twelve months and nearly 28% below its 52-week high of €105.80.

Financial firepower is not the issue. The company sits on a cash position of €16.8 billion and is running a $1 billion share buyback program. At the annual general meeting in May, shareholders elected Iris Löw-Friedrich and Susanne Schaffert to the supervisory board, both seasoned veterans in clinical development and cancer therapy commercialisation — a clear signal that the boardroom is being reshaped for the oncology era.

Whatever the final shape of the GKV-BStabG, it will determine the conditions under which BioNTech’s first oncology products launch in their most important European market. The data from the ROSETTA study may be spectacular, but the regulatory and political climate at home will prove just as decisive.